Study of Botulinum Toxin and Recovery of Hand Function After Stroke - Full Text View

Purpose

The purpose of this study is to determine whether injections of botulinum toxin (commonly known as BOTOX®) into the affected hand of Stroke patients, while targeting the muscles controlling the hand, will lead to improved use of the hand when compared to injections of placebo (a substance that looks similar to the study drug but contains no active study medication).

Condition	Intervention	Phase
Stroke With Hemiparesis	Drug: Botulinum Toxin commonly known as BOTOX®	Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Outcomes Assessor) Primary Purpose: Supportive Care
Official Title:	Botulinum Toxin Type A Therapy as a Plasticity Inducing Agent for Recovery of Hand Function After Stroke

Resource links provided by NLM:

MedlinePlus related topics: Botox

Drug Information available for: OnabotulinumtoxinA

U.S. FDA Resources

Further study details as provided by New York University School of Medicine:

Primary Outcome Measures:

Measurement of Hand function. [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
Assessments are done on day 1, before the 1st Botulinum toxin injection.

They will be assessed for:
- Hand motor impairment (execution and planning) during a functional grasp and lift tasks.
- Hand function.

Secondary Outcome Measures:

Measurement of Hand function [ Time Frame: Day 24 (end of study) ] [ Designated as safety issue: No ]
Subjects will be assessed at the end of 9 weeks after they have completed their training sessions. They will be assessed for:
- change in hand motor impairment (execution and planning) during a functional grasp and lift tasks.
- Hand function.


Enrollment:	24
Study Start Date:	April 2010
Study Completion Date:	April 2015
Primary Completion Date:	February 2015 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Botulinum Toxin commonly known as BOTOX® Some subjects will receive BOTOX® injections. Subject will not be informed of what injection they received.	Drug: Botulinum Toxin commonly known as BOTOX® A total dose between 200-300 units of Botulinum toxin will be administered across 12 muscles of the affected hand. The control group will receive a placebo injection. There will be 1 treatment cycle during the 9 week study. Other Names: BOTOX® Saline
Placebo Comparator: Placebo Some subject will receive a safe Placebo injection. Subjects will not be informed of what injection they have received.	Drug: Botulinum Toxin commonly known as BOTOX® A total dose between 200-300 units of Botulinum toxin will be administered across 12 muscles of the affected hand. The control group will receive a placebo injection. There will be 1 treatment cycle during the 9 week study. Other Names: BOTOX® Saline

Detailed Description:

Hemiparesis is the most common motor impairment after stroke that frequently leads to persistent deficits in hand function. This study investigates whether the application of botulinum toxin to a set of synergistically-acting hand muscles, in conjunction with task-specific therapy, will lead to reorganization and improved motor function in the stroke-involved hand. The investigators will use objective psychophysical measures of hand function and hand function rating scales to investigate if Botox in conjunction with task-specific therapy will lead to:

improved motor execution,
improved motor planning during a psychophysical two-finger grasping and lifting task with varying object weight, and
increased hand function as assessed by the time taken to complete fine motor tasks.

Eligibility


Ages Eligible for Study:	18 Years to 75 Years (Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Ability to follow study instructions and likely to complete all required visits
Ability to comply with the therapy protocol as assessed by the investigator
3 months post first-time unilateral stroke with right or left hemiparesis and complaints of unilateral hand dysfunction
Must have ability to grasp and lift the test object
Subjects must have upper extremity motor impairment

Exclusion Criteria:

Known allergy or sensitivity to botulinum toxin type A (BOTOX).
Females with a positive pregnancy test, or who are breast-feeding, planning a pregnancy during the study, who think that they may be pregnant at the start of the study or females of childbearing potential who are unable or unwilling to use a reliable form of contraception during the study.
Concurrent participation in another investigational drug or device study or participation in another Botulinum toxin study in the 6 months prior to study.
Treatment with botulinum toxin of any serotype in the 3 months prior to study enrollment
Any medical condition that may put the subject at increased risk with exposure to BOTOX including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amytrophic lateral sclerosis, or any other disorder that might interfere with neuromuscular function.
Evidence of alcohol, drug abuse or other relevant neuropsychiatric condition.
Infection or skin disorder at an anticipated injection site.
Any condition or situation that, in the investigator's opinion, may put the subject at significant risk, confound the study results, or interfere significantly with the subject's participation in the study.
History of surgery or other significant injury to either upper extremity causing mechanical limitations that preclude task performance.
Previous neurological illness such as head trauma, prior stroke, epilepsy, or demyelinating disease.
Complicating medical problems such as uncontrolled hypertension, diabetes with signs of polyneuropathy, severe renal, cardiac or pulmonary disease, or evidence of other concurrent neurologic or orthopedic conditions precluding the subject from complying with the study protocol.
Current treatment with intrathecal baclofen.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01422161

Locations


United States, New York
New York University School of Medicine
New York, New York, United States, 10016

Sponsors and Collaborators

New York University School of Medicine

Allergan

Investigators


Principal Investigator:	Preeti Raghavan, MD	New York University School of Medicine

More Information


Responsible Party:	New York University School of Medicine
ClinicalTrials.gov Identifier:	NCT01422161 History of Changes
Other Study ID Numbers:	10-01126 10-01126
Study First Received:	August 19, 2011
Last Updated:	March 31, 2016
Health Authority:	United States: Institutional Review Board

Keywords provided by New York University School of Medicine:


Rehabilitation Fingers Grasp Hand Strength Brain Infraction Pathology	Physiopathology Functional Laterality Neuronal Plasticity Psychomotor Performance Biomechanics Touch Weight-Bearing

Additional relevant MeSH terms:


Stroke Paresis Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular Diseases Neurologic Manifestations Signs and Symptoms OnabotulinumtoxinA Botulinum Toxins, Type A	AbobotulinumtoxinA IncobotulinumtoxinA Botulinum Toxins Acetylcholine Release Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Cholinergic Agents Neurotransmitter Agents Physiological Effects of Drugs Neuromuscular Agents Peripheral Nervous System Agents

ClinicalTrials.gov processed this record on September 30, 2016